13F Holdings
中文EN

APTN ADAPTIN BIO, INC.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1938571 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.4%
TTM EPS YoY30.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-452.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets253.9%
Debt / equity—
Current ratio0.39x
Interest coverage-485.91x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$1.77M$1.82M—
SG&A expense$3.64M$745,294$85,593
Operating income-$5.41M-$2.57M-$85,593
Interest expense$72,659$341,048—
Pretax income-$5.17M-$3.12M—
Net income-$5.17M-$3.12M-$85,593
EPS (basic)-0.66-0.96-0.02
EPS (diluted)-0.66-0.96-0.02
Weighted avg. shares (diluted)7.81M3.25M5.00M
Balance sheet
Cash & equivalents$459,174$34,085$4,754
Current assets$619,159$45,539$380
Total assets$619,159$239,415$380
Current liabilities$2.11M$4.34M$113,277
Total liabilities$2.11M$4.34M$113,277
Shareholders' equity-$1.49M-$4.10M-$977,559
Shares outstanding8.66M3.25M5.00M
Cash flow statement
Operating cash flow-$4.78M-$649,283-$81,035
Financing cash flow$5.20M$678,614$80,915
Stock-based compensation$496,864——

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.